Drug intelligence / Profile preview

EC-303

Development stage: Preclinical
Lead developer: Eclipse Life Sciences
Modality: Small Molecules
Administration: Ophthalmic

Overview

EC-303 is a novel mitochondria-targeted small molecule prodrug being developed by Eclipse Life Sciences for the treatment of Dry Age-Related Macular Degeneration (Dry AMD). The drug is formulated for intravitreal administration using a proprietary multiphasic colloidal suspension-drug delivery system, which enables extended-release delivery to the back of the eye. EC-303 is designed to act on mitochondrial function to provide anti-degenerative and neuroprotective effects in the retina, aiming to preserve vision in patients with progressive retinal diseases. It is currently in the preclinical stage, specifically undergoing IND-enabling studies.

Beyond the preview

Go deeper on EC-303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EC-303.

Explore the full profile